Coherus Oncology, Inc. CHRS
Coherus Oncology, Inc. (Nasdaq: CHRS) is an oncology drug developer. Its lead program, LOQTORZI (toripalimab-tpzi), is in Phase 2 for Nasopharyngeal carcinoma (1L with cisplatin/gemcitabine; monotherapy after platinum).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| LOQTORZI (toripalimab-tpzi), anti-PD-1 | Nasopharyngeal carcinoma (FDA approved Oct 2023; US launch Jan 2024) | antibody | Approved |
| casdozokitug (CHS-388), anti-IL-27 | 1L hepatocellular carcinoma, with toripalimab and bevacizumab | antibody | Phase 2 |
| tagmokitug (CHS-114), anti-CCR8 | HNSCC, upper GI adenocarcinoma, ESCC, colorectal cancer (Phase 1b/2a) | antibody | Phase 1 |
Recent results and decisions
- Oct 28, 2026positive Tagmokitug plus toripalimab and chemotherapy achieved 75% confirmed ORR overall and 100% in PD-L1-positive first-line ESCC patients in Phase 1b TREGCHECK 102 Cohort C.
In evaluable front-line esophageal squamous cell carcinoma (ESCC) patients, tagmokitug in combination with toripalimab and chemotherapy demonstrated a confirmed overall response rate (cORR) of 75% irrespective of PD-L1 status, and a cORR of 100% in PD-L1 positive patients as of October 14, 2026.
Filing - Oct 14, 2026positive Tagmokitug combination achieved 75% confirmed ORR (100% in PD-L1 positive patients) in first-line ESCC, updated to 89% cORR post-data-cutoff.
In evaluable front-line esophageal squamous cell carcinoma (ESCC) patients, tagmokitug in combination with toripalimab and chemotherapy demonstrated a confirmed overall response rate (cORR) of 75% irrespective of PD-L1 status, and a cORR of 100% in PD-L1 positive patients as of October 14, 2026.
Filing - May 11, 2026completed enrollment Enrollment completed in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC.
Enrollment is complete in the randomized Phase 2 trial of casdozokitug/toripalimab/bevacizumab in 1L uHCC and the first data readout is expected in mid-2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.